Prognose

Kaufen	12
Halten	5
Verkaufen	0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
LEXINGTON, Mass.--(BUSINESS WIRE)--Novo Nordisk today announced that the acquisition of Dicerna, announced on 18 November 2021, has been completed.» Mehr auf businesswire.com
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
LEXINGTON, Mass.--(BUSINESS WIRE)--Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna’s common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021, which represent approximately 82.6% of the total number of shares of Dicerna’s common stock outstanding. Following the finalisation of the tender offer, Novo Nordisk completed the acquisition of Dicerna today through a merger of Novo Nordisk’s wholly owned subsidiary with and into Dicerna in which all shares not tendered into the offer were cancelled and converted into the right to receive cash equal to the USD 38.25 offer price per share, without interest, less any applicable tax withholding. At the completion of the merger, Dicerna became a wholly owned subsidiary of Novo Nordisk. The common stock of Dicerna will no longer be listed or traded on the Nasdaq Global Select Market. About the acquisition For more information, please see: Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.» Mehr auf businesswire.com
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna» Mehr auf businesswire.com

Unternehmenszahlen

Im letzten Jahr hatte Dicerna Pharmaceuticals einen Umsatz von 134,91 Mio€ und ein Nettoeinkommen von −92,58 Mio€

(EUR)	2020	YOY
Umsatz	+134,91 Mio	533,25%
Bruttoeinkommen	+134,91 Mio	533,25%
Nettoeinkommen	−92,58 Mio	13,77%
EBITDA	−90,74 Mio	14,59%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	0,00€
52 Wochen-Hoch/Tief	+32,46€ - +32,44€
Dividenden	Nein
Beta	0,79
KGV (PE Ratio)	−25,26
KGWV (PEG Ratio)	−0,25
KBV (PB Ratio)	+20,68
KUV (PS Ratio)	0,00

Unternehmensprofil

Dicerna Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Entdeckung, Entwicklung und Vermarktung von Arzneimitteln auf Basis von Ribonukleinsäure-Interferenz (RNAi) konzentriert. Das Unternehmen entwickelt Pharmazeutika unter Verwendung seiner GalXC-RNAi-Plattform zur Behandlung von Krankheiten, die die Leber betreffen, einschließlich seltener, kardiometabolischer, viraler und chronischer Lebererkrankungen, komplementvermittelter Krankheiten sowie neurodegenerativer Erkrankungen und Schmerzen. Zu den wichtigsten Entwicklungsprogrammen des Unternehmens gehören Nedosiran zur Behandlung der primären Hyperoxalurie, RG6346 zur Behandlung der chronischen Hepatitis-B-Virusinfektion, Belcesiran zur Behandlung der Mangel-assoziierten Lebererkrankung und DCR-AUD zur Behandlung der Alkoholkrankheit. Dicerna Pharmaceuticals, Inc. unterhält strategische Kooperationen mit Novo Nordisk A/S, F. Hoffmann-La Roche Ltd. und Hoffmann-La Roche Inc. sowie mit Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. und Boehringer Ingelheim International GmbH. Das Unternehmen wurde im Jahr 2006 gegründet und hat seinen Hauptsitz in Lexington, Massachusetts. Ab dem 27. Dezember 2021 ist Dicerna Pharmaceuticals, Inc. eine Tochtergesellschaft von Novo Nordisk A/S.